Epia Neuro Launches with a Minimally Invasive Brain-Computer Interface Designed to Restore Hand Function After Stroke
Epia Neuro emerged from stealth on April 2 with a read/write BCI platform that decodes neural intent and drives a grip-assist prosthetic, targeting first-in-human trials at Lenox Hill Hospital later this year.
Overview
Epia Neuro, a neurotechnology startup building intent-driven brain-computer interfaces for stroke survivors, formally launched on April 2, 2026, according to a BusinessWire press release. The company is developing a minimally invasive implant that decodes neural signals in real time and translates them into functional movement through an external grip-assist prosthetic, with first-in-human system demonstrations planned at the Department of Neurosurgery at Lenox Hill Hospital in New York later this year.
The announcement adds another entrant to a rapidly expanding BCI sector. Where recent clinical milestones from Neuralink and BrainGate have focused on communication for patients with ALS and paralysis, Epia Neuro is targeting a far larger patient population: the estimated 690,000 Americans who survive a stroke each year, roughly 60,000 of whom the company believes could be candidates for its system.
How the Technology Works
Epia Neuro’s platform consists of three integrated components: a surgically implanted neural interface, AI-driven signal processing software, and an external assistive device, as described in the company’s launch announcement.
The implant is placed within the skull in a procedure the company says takes under one hour and does not pierce the dura membrane, the protective layer surrounding the brain. This subdural approach contrasts with the penetrating electrode arrays used by companies like Neuralink and BrainGate, which insert electrodes directly into brain tissue. Once in place, the device is externally invisible and recharged wirelessly through a non-invasive headset, according to Fierce Biotech.
Unlike many existing BCIs that can only record neural activity, Epia Neuro’s system supports both sensing and stimulation at cortical and deep-brain levels, creating what the company describes as a “read/write” interface. The AI layer fuses neural signals with contextual data from external sensors to predict user intent, then drives an upper-limb grip-assist motor prosthetic designed to help stroke survivors regain functional hand movement, according to the press release.
Leadership and Origins
The company is led by CEO Michel Maharbiz, a serial entrepreneur and former professor of electrical engineering and bioengineering at the University of California, Berkeley. Maharbiz previously founded iota Biosciences, a bioelectronics company now powered by Astellas Pharma, whose technology Epia Neuro’s platform advances, according to BusinessWire.
The leadership team also includes Chief Technology and Science Officer Gil Mandelbaum, who brings more than 15 years of experience in neuroscience hardware and software development, and COO Michelle Patruno, who has over 15 years of experience scaling organizations through IPO, as detailed in the same announcement.
Market Opportunity and Clinical Path
Stroke is a leading cause of long-term disability in the United States. Epia Neuro estimates that approximately 60,000 stroke survivors annually could be eligible for its products, representing a domestic market opportunity the company values at more than five billion dollars, according to its press release. Beyond stroke, the company plans to expand into cognitive decline and other neurological conditions targeting the growing aging population.
The company has not disclosed total funding or specific investor names beyond noting its iota Biosciences lineage.
What We Don’t Know
Several critical questions remain unanswered. Epia Neuro has not published peer-reviewed clinical data on its platform, and the planned Lenox Hill demonstrations will be the first time the system is tested in human subjects. The company has not disclosed how many participants will be enrolled, the study’s primary endpoints, or the regulatory pathway it intends to pursue for eventual commercial approval.
The long-term durability and safety profile of the subdural implant also remain unproven. While avoiding dura penetration may reduce surgical risk compared to penetrating arrays, the tradeoff in signal resolution and decoding accuracy has not been publicly characterized. How the system performs relative to existing BCI platforms in controlled comparisons is unknown.
Pricing and insurance coverage for a combined implant-plus-prosthetic system represent additional unknowns that will determine whether the technology reaches the stroke survivors who need it most.
Wider Context
Epia Neuro’s launch arrives during a period of accelerating BCI commercialization. As STAT News reported in its 2026 outlook, participation in clinical trials testing brain implants has grown from single digits to dozens of patients, with multiple companies securing FDA breakthrough device designations. The field is also broadening beyond its historical focus on paralysis and ALS toward more prevalent conditions, including memory loss from traumatic brain injury and now stroke rehabilitation.
Whether Epia Neuro can translate its engineering ambitions into clinical evidence will depend on the Lenox Hill trials. For the millions of stroke survivors living with motor impairment, the stakes extend well beyond the laboratory.